Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab for Bone Health in Women with SCI and Osteoporosis
NCT04708886Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Mar 2021
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romosozumab in osteoporosis, sponsored by Northwestern University. Primary endpoint: Change in Integral Volumetric Bone Mineral Content at the Knee (Distal Femur) at 12 months. Started Mar 2021; status: completed.
02
Drugs
romosozumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT04708886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04708886.